Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention

Area of Science:

• Rheumatology and Pulmonology
• Autoimmune diseases
• Fibrotic lung diseases

Background:

• Systemic sclerosis (SSc) is a progressive autoimmune disease.
• Interstitial lung disease (ILD) is a major complication and cause of mortality in SSc patients.
• Lung function decline is most rapid in the first 3-4 years of SSc onset.

Purpose of the Study:

• To provide an overview of SSc-associated ILD (SSc-ILD).
• To highlight current and emerging diagnostic tools for early detection.
• To review existing and novel therapeutic strategies for SSc-ILD.

Main Methods:

• Review of current literature on SSc-ILD diagnosis and treatment.
• Emphasis on thoracic high-resolution computed tomography (HRCT) for early detection and monitoring.
• Discussion of approved and investigational therapies.

Main Results:

• Thoracic HRCT is crucial for detecting and monitoring SSc-ILD.
• Cyclophosphamide and mycophenolate mofetil are common treatments.
• Nintedanib, an antifibrotic, is approved to slow pulmonary function decline in SSc-ILD.

Conclusions:

• Early detection of SSc-ILD is key for timely intervention.
• Nintedanib represents a significant advancement in SSc-ILD treatment.
• Further research into novel antifibrotic and disease-modifying therapies is needed to improve patient outcomes.